EpCAM (CD326) finding its role in cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Epithelial cell adhesion molecule (EpCAM/CD326), identified early as a tumor-associated antigen, has been historically under-investigated for cancer therapy.
• The specific role of EpCAM in carcinogenesis remained largely unexplored until recent advancements.
• The First International Symposium on EpCAM Biology and Clinical Application marked a turning point in EpCAM research.

Purpose of the Study:

• To consolidate current knowledge and future directions regarding EpCAM in cancer.
• To discuss EpCAM's expression, prognostic value, and oncogenic signaling roles.
• To review EpCAM-directed immunotherapeutic strategies and potential therapeutic windows.

Main Methods:

• Discussion and synthesis of findings presented at the First International Symposium on EpCAM Biology and Clinical Application.
• Review of existing literature on EpCAM expression, function, and therapeutic targeting.
• Analysis of EpCAM's interaction with other proteins for therapeutic insights.

Main Results:

• EpCAM expression frequency and levels across various cancers and their prognostic significance were key discussion points.
• EpCAM's function as an oncogenic signaling molecule in cancer cells was highlighted.
• Progress in EpCAM-directed immunotherapies and potential strategies to inhibit its growth-promoting signaling were presented.

Conclusions:

• EpCAM is gaining recognition as a significant target for cancer therapy and research.
• Understanding EpCAM's multifaceted roles in carcinogenesis is crucial for developing effective treatments.
• Future research should focus on unified nomenclature and interdisciplinary collaboration for EpCAM-targeted therapies.